| 000 | 00834 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250517114109.0 | ||
| 264 | 0 | _c20180112 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a1528-0020 | ||
| 024 | 7 |
_a10.1182/blood-2016-07-724948 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDaver, Naval | |
| 245 | 0 | 0 |
_aCotargeting BCL-2 and BCL-XL for maximal efficacy in ALL. _h[electronic resource] |
| 260 |
_bBlood _c09 2016 |
||
| 300 |
_a1316-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aProto-Oncogene Proteins c-bcl-2 |
| 650 | 0 | 4 | _abcl-X Protein |
| 700 | 1 | _aKonopleva, Marina | |
| 773 | 0 |
_tBlood _gvol. 128 _gno. 10 _gp. 1316-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2016-07-724948 _zAvailable from publisher's website |
| 999 |
_c26402454 _d26402454 |
||